Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates
Bryan E. Jones, Patricia Brown‐Augsburger, Kizzmekia S. Corbett, et al.
Science Translational Medicine (2021) Vol. 13, Iss. 593
Open Access | Times Cited: 427

Showing 1-25 of 427 citing articles:

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
Yunlong Cao, Jing Wang, Fanchong Jian, et al.
Nature (2021) Vol. 602, Iss. 7898, pp. 657-663
Open Access | Times Cited: 1769
Considerable escape of SARS-CoV-2 Omicron to antibody neutralization
Delphine Planas, Nell Saunders, Piet Maes, et al.
Nature (2021) Vol. 602, Iss. 7898, pp. 671-675
Open Access | Times Cited: 1456
Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2
Lihong Liu, Sho Iketani, Yicheng Guo, et al.
Nature (2021) Vol. 602, Iss. 7898, pp. 676-681
Open Access | Times Cited: 1263
BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection
Yunlong Cao, Ayijiang Yisimayi, Fanchong Jian, et al.
Nature (2022) Vol. 608, Iss. 7923, pp. 593-602
Open Access | Times Cited: 1218
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
Elisabetta Cameroni, John E. Bowen, Laura E. Rosen, et al.
Nature (2021) Vol. 602, Iss. 7898, pp. 664-670
Open Access | Times Cited: 1113
The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic
Markus Hoffmann, Nadine Krüger, Sebastian Schulz, et al.
Cell (2021) Vol. 185, Iss. 3, pp. 447-456.e11
Open Access | Times Cited: 875
Antibody evasion properties of SARS-CoV-2 Omicron sublineages
Sho Iketani, Lihong Liu, Yicheng Guo, et al.
Nature (2022) Vol. 604, Iss. 7906, pp. 553-556
Open Access | Times Cited: 790
An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
Laura A. VanBlargan, John M. Errico, Peter Halfmann, et al.
Nature Medicine (2022) Vol. 28, Iss. 3, pp. 490-495
Open Access | Times Cited: 714
Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5
Qian Wang, Yicheng Guo, Sho Iketani, et al.
Nature (2022) Vol. 608, Iss. 7923, pp. 603-608
Open Access | Times Cited: 714
Neutralizing monoclonal antibodies for treatment of COVID-19
Peter C. Taylor, Andrew C. Adams, Matthew M. Hufford, et al.
Nature reviews. Immunology (2021) Vol. 21, Iss. 6, pp. 382-393
Open Access | Times Cited: 713
Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance
Jiahui Chen, Rui Wang, Nancy Benovich Gilby, et al.
Journal of Chemical Information and Modeling (2022) Vol. 62, Iss. 2, pp. 412-422
Open Access | Times Cited: 640
SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern
Matthew McCallum, Jessica Bassi, Anna De Marco, et al.
Science (2021) Vol. 373, Iss. 6555, pp. 648-654
Open Access | Times Cited: 441
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants
Kathryn Westendorf, Stefanie Žentelis, Lingshu Wang, et al.
Cell Reports (2022) Vol. 39, Iss. 7, pp. 110812-110812
Open Access | Times Cited: 402
mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant
Henning Gruell, Kanika Vanshylla, Pinkus Tober‐Lau, et al.
Nature Medicine (2022) Vol. 28, Iss. 3, pp. 477-480
Open Access | Times Cited: 401
Tackling COVID-19 with neutralizing monoclonal antibodies
Davide Corti, Lisa A. Purcell, Gyorgy Snell, et al.
Cell (2021) Vol. 184, Iss. 12, pp. 3086-3108
Open Access | Times Cited: 373
Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy
Qianqian Zhang, Rong Xiang, Shanshan Huo, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 308
Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies
Florian A. Lempp, Leah Soriaga, Martin Montiel-Ruiz, et al.
Nature (2021) Vol. 598, Iss. 7880, pp. 342-347
Closed Access | Times Cited: 299
Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies
Timothée Bruel, Jérôme Hadjadj, Piet Maes, et al.
Nature Medicine (2022) Vol. 28, Iss. 6, pp. 1297-1302
Open Access | Times Cited: 290
Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants
Matthew McCallum, Alexandra C. Walls, Kaitlin R. Sprouse, et al.
Science (2021) Vol. 374, Iss. 6575, pp. 1621-1626
Open Access | Times Cited: 287
Structures of the Omicron spike trimer with ACE2 and an anti-Omicron antibody
Wanchao Yin, Youwei Xu, Peiyu Xu, et al.
Science (2022) Vol. 375, Iss. 6584, pp. 1048-1053
Open Access | Times Cited: 271
An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment
Sylwester Drożdżal, Jakub Rosik, Kacper Lechowicz, et al.
Drug Resistance Updates (2021) Vol. 59, pp. 100794-100794
Open Access | Times Cited: 264
In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains
Rita E. Chen, Emma S. Winkler, James Brett Case, et al.
Nature (2021) Vol. 596, Iss. 7870, pp. 103-108
Open Access | Times Cited: 252
The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies
Richard Copin, Alina Baum, Elzbieta Wloga, et al.
Cell (2021) Vol. 184, Iss. 15, pp. 3949-3961.e11
Open Access | Times Cited: 213
Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection
Yu‐Chyi Hwang, Ruei‐Min Lu, Shih-Chieh Su, et al.
Journal of Biomedical Science (2022) Vol. 29, Iss. 1
Open Access | Times Cited: 203
Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities
Myron S. Cohen, Ajay Nirula, Mark J. Mulligan, et al.
JAMA (2021) Vol. 326, Iss. 1, pp. 46-46
Open Access | Times Cited: 196
Page 1 - Next Page

Scroll to top